Adverse Effects in Neonates Exposed to SSRIs and SNRI in Late Gestation

Main Article Content

Gideon Koren
Nina Boucher

Keywords

Neonates, SSRIs, SNRI, Late Gestation

Abstract

Neonates exposed at term to selective serotonine (SSRI) or serotonine-norepinephrine reuptake inhibitors (SNRI) medications may encounter symptoms such as irritability, rigidity, tremor and respiratory distress. Most available data suggest that these self limited symptoms are due to discontinuation  of  the  drug, although  there  are documented cases of symptoms associated with high serum concentrations in the neonate that subsided when levels fall. Preliminary evidence suggests that the very early respiratory symptoms may not be part of discontinuation but rather part of a reversible form of persistent pulmonary hypertension of the newborn (PPHN).

Abstract 375 | PDF Downloads 99

References

1. Haddad PM, Dursun SM. Neurological complications of psychiatric drugs: clinical features and management. Hum Psychopharmcol 2008; 1: 15-26.
2. Koren G, Matsui D, Einarson A, Knoppert D, Steiner M. Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates? CMAJ 2005; 172: 1457-9.
3. Knoppert DC, Nimkar R, Principi T, Yuen D. Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels. Ther Drug Monit 2006; 28: 5-7.
4. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchell AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 579-87.
5. Kallen B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008; 17: 801-6.
6. Fornaro E, Li D, Pan J, Belik J. Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat. Am J Respir Crit Care Med 2007; 176: 1035-40.

Most read articles by the same author(s)

<< < 4 5 6 7 8 9 10 > >>